"To address the deficiencies of the Patents Act 1953, Cabinet, in August 2001, agreed to a 3-stage review of the Act. The proposals discussed in this regulatory impact statement are part of Stage 2 of this Review. Cabinet has previously agreed to proposals in Stage 1 (August 2001) and the first part of Stage 2 (September 2001). Contentious issues including Māori and other concerns regarding issues such as the patentability of biotechnological inventions, medical treatments, and computer software and business methods, will be dealt with in Stage 3 of the review. The criteria for granting a patent contained in the Patents Act 1953 are less stringent than the criteria now applied in most other developed countries, including New Zealand’s major trading partners. This means that patents granted in New Zealand provide a broader monopoly than would be provided for the same invention in other countries."